Regarding the effect of CTLA-4 inhibition on acquired resistance, even though the addition of CTLA-4 inhibitors could raise the tails of DoR KM curves in some studies (i.e., Checkmate 227 and Checkmate 9LA) compared to anti-PD-1 agents, we did not observe a clear role for CTLA-4 inhibitors in reducing acquired resistance risk and prolonging DoR in patients with NSCLC receiving a PD-1/PD-L1 blockade backbone. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.